Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The Blacklisting of Peptides The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026)